1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Vital Signs The Analyst's Perspective - December 2015 Issue

Vital Signs The Analyst's Perspective - December 2015 Issue

  • February 2016
  • -
  • Frost & Sullivan
  • -
  • 7 pages

The Analyst’s Perspective by Barbara Gilmore, Senior Industry Analyst, Life Sciences Internationally, drug prices are held in check by government-monitored drug pricing regulations. Countryspecific, government-run health systems have long regulated country-specific drug pricing. The most commonly used practice to set drug pricing is based on a process called “reference pricing.” In the European Union (EU), member countries are free to develop their own country’s national and regional pricing. Historical practices coupled with political, legal, and economic considerations mean there are presently a variety of different country-specific pricing regulations implemented across EU. Reference pricing is the most commonly used practice to contain costs and reduce pricing for on-patent drugs in the EU.

Most countries set the price for a given drug by looking at the price for the same drug in a variety of countries. The “group” of countries used to compared prices are referred to as “country baskets.” The most referenced country is France (19), followed by the UK and Germany (17 each). The least referenced countries are Switzerland (two), Iceland (three), and Norway (six). Where there is no reference price available for a reference country for a drug, or the drug is not yet approved in some of the reference countries, the available country data is used. Prices can be adjusted as products become more widely available.1 Germany was the first EU country to institute reference pricing. At first it was based on the class of drug, but has evolved to a system of therapeutic comparability, looking at active ingredients, therapeutically comparable active ingredients, and comparable pharmacological profiles.

In Norway, the state-run health system, in addition to looking at reference country pricing, bargains with the drug company, requesting proof of the drug’s value in comparison to the existing marketed therapeutics. In Norway, the state pays for most prescription drugs, though patients sometimes have co-pay requirements.2 In Canada, reference pricing was introduced for five drug classes, which represent the largest portion of the national drug budget, including NSAIDs, histamine-2 receptor antagonists, oral nitrates, ACE inhibitors, and calcium channel blocker.3 In Japan, the Ministry of Health, Labor and Welfare (MHLW) establishes the drug reimbursement prices for pharmaceuticals.

The MHLW works with the Central Social Insurance Medical Council (CSIMC) to set reimbursement rates. When a new drug is launched, the reimbursement for that drug depends on whether there is an approved comparable drug. If there is, the new drug must be innovative or more efficacious to be able to get premium pricing, which is considered to be % higher. If no comparable drug exists, the price is determined by taking the manufacturing costs, administration, and marketing costs into account. If there are generics already available, the new drug is set at the lowest price of an available generic. If there is no generic available, the price is set at % of the original drug price.

Table Of Contents

Vital Signs The Analyst's Perspective - December 2015 Issue
Why the US Pays More than Other Countries for Drugs 2
The Body Electric: The Inside Story on Wearable Electronics 3
Mosquito Borne: Spreading Virus Adding to Brazil's Woes 4
US Drug Costs Soaring: Patients Struggle with High Drug Prices 5

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.